Ticker News
$FBLG News
Stored TradersLink news articles and press-release context for this ticker. Discord alerts link into these article pages when full article text is available.
Published Articles
Latest saved alerts
FBLG to sell ~4.08M shares + warrants in $3.0M at‑the‑market private placement (up to $9.0M)
FibroBiologics (FBLG) agreed to sell an aggregate of 4,081,633 shares of common stock (or pre‑funded warrants in lieu) together with Series A and short‑term Series B warrants in a private placement priced at‑the‑market at $0.735 per share, expected to raise approximately $3.0M upfront and up to an additional ~$6.0M if warrants are fully exercised (total potential $9.0M). The offering is expected to close on or about June 29, 2026; the warrants are exercisable only after the company obtains the required stockholder approval and the resale registration is effective, so initial dilution occurs at closing for the issued shares/prefunded warrants while further dilution from warrant exercises is delayed pending approval and exercise. Timing: Dilution depends on stockholder approval first, and the press release does not say when that will happen.
USPTO allows FibroBiologics patent for topical fibroblast‑spheroid wound therapy
The USPTO issued a Notice of Allowance for U.S. Patent Application No. 18/184,726 covering topical administration of 3D spheroid fibroblasts, alone or with fibroblast-derived materials, to treat and accelerate healing of wounds including chronic wounds and wounds in diabetic patients. The allowed claims map directly to FibroBiologics' lead program CYWC628 (an allogeneic topical fibroblast‑spheroid therapy currently in a Phase 1/2 diabetic foot ulcer trial), strengthening IP around the clinical approach though no clinical efficacy data were reported.
FBLG: First patients dosed in Phase 1/2 trial of CYWC628 for diabetic foot ulcers
FibroBiologics (FBLG) announced the first patients have been enrolled and dosed in its randomized, multicenter Phase 1/2 trial of CYWC628 — a topically administered allogeneic fibroblast-spheroid therapy — for diabetic foot ulcers in Australia, with up to 120 patients randomized to standard of care (SoC) alone or SoC plus low or high dose CYWC628. The study will evaluate safety, tolerability and efficacy over up to 12 weeks with an interim analysis after six weeks; preclinical data suggest accelerated wound healing but no human efficacy data are reported yet.
FBLG doses first patients in Phase 1/2 diabetic foot ulcer trial
FibroBiologics said it has enrolled and dosed the first patients in its Phase 1/2 trial of CYWC628, an investigational topical allogeneic fibroblast‑spheroid therapy for diabetic foot ulcers. The randomized, multicenter Australian study will enroll up to 120 patients comparing standard of care (SoC) alone versus SoC plus low or high dose CYWC628, with an interim analysis after six weeks and interim data expected in Q3 2026 (primary results by end of 2026); the company recently raised $3M.